MRNA vs SMMT
MRNA: Moderna is a pioneer in mRNA technology, working to transform medicine by developing a broad pipeline of prophylactic vaccines and therapeutic medicines. SMMT: A biopharmaceutical company dedicated to the clinical advancement of its lead bispecific antibody, ivonescimab, for oncology applications.
Side-by-side fundamentals
| Metric | MRNA | SMMT | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $57.92 | $13.10 | |
| Market cap as of 2026-08-01 | $23.0B | $10.2B | |
| PEG as of 2026-08-01 | n/a | -1.08 | |
| Net margin as of 2026-08-01 | -143.6% | -9027.1% | MRNA higher |
| Gross margin as of 2026-08-01 | +35.0% | n/a | |
| Operating margin as of 2026-08-01 | -153.3% | -8108.3% | MRNA higher |
| ROE as of 2026-08-01 | -36.7% | -168.9% | MRNA higher |
| ROA as of 2026-08-01 | -26.6% | -141.9% | MRNA higher |
| Debt / equity as of 2026-08-01 | 0.09 | 0.00 | SMMT lower |
| Revenue growth (YoY) as of 2026-08-01 | -30.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -53.4% | n/a | |
| Beta as of 2026-08-01 | 0.88 | -1.33 | |
| 1-year return as of 2026-07-30 close | +80.2% | -54.3% | MRNA higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.